Point72 Asset Management L.P. purchased a new stake in Zura Bio Limited (NASDAQ:ZURA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 2,413,127 shares of the company's stock, valued at approximately $8,446,000. Point72 Asset Management L.P. owned about 5.54% of Zura Bio as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the business. Renaissance Technologies LLC raised its holdings in Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock valued at $61,000 after acquiring an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock valued at $165,000 after acquiring an additional 6,412 shares during the last quarter. Forefront Analytics LLC raised its holdings in Zura Bio by 46.8% in the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company's stock valued at $99,000 after acquiring an additional 6,765 shares during the last quarter. AQR Capital Management LLC acquired a new position in Zura Bio in the 2nd quarter valued at $43,000. Finally, Armistice Capital LLC raised its holdings in Zura Bio by 15.4% in the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company's stock valued at $8,518,000 after acquiring an additional 244,000 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.
Zura Bio Stock Performance
Shares of ZURA stock traded up $0.12 during trading hours on Wednesday, hitting $3.97. 238,197 shares of the company were exchanged, compared to its average volume of 325,436. Zura Bio Limited has a one year low of $2.00 and a one year high of $7.22. The business's 50-day simple moving average is $3.79 and its two-hundred day simple moving average is $3.82.
Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Equities analysts anticipate that Zura Bio Limited will post -0.47 earnings per share for the current fiscal year.
Insider Activity
In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 15.80% of the company's stock.
Wall Street Analysts Forecast Growth
ZURA has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a report on Thursday, August 15th. Piper Sandler restated an "overweight" rating and set a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. Finally, HC Wainwright initiated coverage on Zura Bio in a report on Thursday, September 5th. They set a "neutral" rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.50.
Check Out Our Latest Analysis on ZURA
Zura Bio Company Profile
(
Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Featured Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
